Skip to main content
. 2024 Aug 8;37(11):doae059. doi: 10.1093/dote/doae059

Fig. 1.

Fig. 1

Survival analysis: (Abbreviations: (definitive/neoadjuvant) chemoradiotherapy [(d/n)CRT]). (A) Two-year overall survival for patients with nCRT (70%) and patients with dCRT (66%, P = 0.67). (B) Two-year cancer-specific survival for patients with nCRT (73%) and patients with dCRT (80%, P = 0.41).